NCT00822302View on ClinicalTrials.gov

Trial to Evaluate the Ability of a Single Infusion of High-Density Lipoprotein (HDL) to Modulate Markers of Cerebral Ischaemia

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

February 28, 2009

Conditions
Stroke
Interventions
DRUG

Reconstituted High Density Lipoprotein

RecHDL (Lot Nos 05422-00006)is provided as a lyophilised powder and reconstituted with sterile water at 25 mg/ml. The infusion is made at 40 mg/kg over a period of 4 hours.

DRUG

Saline

Saline (0.9%) is provided as a sterile infusion bag and infused over a period of 4 hours, 24 hours prior to carotid endarterectomy

Trial Locations (1)

SW17 0QT

St Georges University of London, London

All Listed Sponsors
lead

St George's, University of London

OTHER

NCT00822302 - Trial to Evaluate the Ability of a Single Infusion of High-Density Lipoprotein (HDL) to Modulate Markers of Cerebral Ischaemia | Biotech Hunter | Biotech Hunter